Additionally, canakinumab, a human monoclonal IL-1β antibody, and rilonacept, a decoy receptor of IL-1α and IL-1β, have been targeted in rheumatoid arthritis (Swanson et al., 2019). This evidence concerns the gene IL1A and rheumatoid arthritis.